Marketdash
Back to News

BenQ BM Takes Another Shot at Hong Kong IPO After Two Failed Attempts

MarketDash Editorial Team
19 days ago
Private hospital operator BenQ BM is trying for a third time to list in Hong Kong, but shrinking revenues and declining profits may leave investors wondering if the third time really is the charm.

You know what's worse than failing to launch an IPO once? Trying again with financials that haven't gotten any better. That's the situation facing BenQ BM Holding Cayman Corp., a private hospital operator in China that's taking its third crack at a Hong Kong listing after two previous attempts fizzled out.

The company filed a new prospectus last week, reviving a listing plan that first launched back in April 2024. BenQ BM is majority owned by Qisda (2352.TW), a Taiwan-listed company known globally for its LCD displays and projectors. But if you're thinking this is a story about tech expansion into healthcare with Silicon Valley-style growth numbers, think again.

The Promise and the Problem

On paper, private healthcare in China sounds like a great investment story. The population is aging rapidly, the middle class is expanding, and people increasingly want better service than what they get at overcrowded public hospitals. Who hasn't heard horror stories about the cattle-call experience at massive state-run medical facilities?

But reality is messier than the pitch deck. Private hospitals in China face intense regulatory scrutiny because, well, they're dealing with public health. They compete against government-backed public hospitals that are under pressure to operate more profitably. Hiring qualified doctors is harder when public hospitals can offer better job security and benefits. There's also lingering public skepticism that private operators might put profits ahead of patient care. And let's not forget the basic economics: private hospitals are more expensive to run because they don't get the cost advantages and connections that state-owned peers enjoy.

BenQ BM's financial performance illustrates these challenges vividly. Revenue slipped 1% to 2.7 billion yuan ($380 million) in 2024 from the prior year, and declined by a similar amount year-on-year in the first half of 2025. Worse, profitability is deteriorating steadily. The company's net margin dropped from 6.2% in 2023 to 4.1% in 2024, then fell further to 3.7% in the first half of this year. That's not the trajectory investors typically get excited about.

Maxed Out and Squeezed

A big part of BenQ BM's revenue problem comes down to physical space. The company operates two hospitals: Nanjing BenQ Hospital, a Grade-A Class 3 facility that opened in 2008, and Suzhou BenQ Hospital, a Class 3 general hospital established in 2013. Together they have 1,850 beds as of the end of June, a number that hasn't budged since Nanjing added 150 beds in 2023.

The Nanjing facility is so full that its bed occupancy rate exceeds 100% with temporary beds in use. It's essentially maxed out. Suzhou isn't much better, running at nearly 90% occupancy. When you're already at capacity, there's not much room to grow inpatient revenue, and inpatient services account for just over half of BenQ BM's total revenue.

Then there's the regulatory squeeze. Three years ago, Jiangsu province (where both hospitals are located) introduced a diagnosis-related group (DRG) payment system. Under this scheme, China's public medical insurance reimburses hospitals at standardized rates for inpatient services based on diagnosis categories, rather than actual treatment costs. If those standardized payments don't cover what it actually costs to treat someone, the hospital eats the difference.

Since the DRG system rolled out, average spending per inpatient visit at both BenQ hospitals has declined substantially. Average spending per outpatient visit has also fallen, even as visitor numbers increased, thanks to a government program for centralized drug procurement aimed at lowering drug prices. Add in adjustments to reimbursement rules for certain diagnostic procedures, and you've got a picture of the Chinese government systematically trying to keep healthcare affordable for its national health plan and patients—which is great policy, but not great for hospital margins.

Sure, the centralized drug purchasing program has helped BenQ BM reduce pharmaceutical costs somewhat. But the broader revenue pressure from regulatory changes shows just how much the company's fortunes depend on government policy in this heavily regulated industry.

David Among Many Goliaths

Competition isn't doing BenQ BM any favors either. The company controls a minuscule 0.4% market share among private for-profit hospital operators in China, according to its prospectus. Its Nanjing hospital is the largest in Jiangsu province but still only commands 2% of that provincial market.

Zoom out to include public hospitals, and BenQ's position looks even tinier. Private hospitals collectively generated 944.7 billion yuan in revenue last year—less than a quarter of what government-owned hospitals brought in.

To stay competitive, BenQ BM needs to hire top-tier doctors, which doesn't come cheap. Employee expenses have climbed due to new hires, especially senior professionals like chief doctors. That's putting pressure on gross margin, which slid to 15.9% in the first half of 2025 from 19.3% a year earlier.

The Growth Gambit

If BenQ BM does manage to pull off this IPO, the company plans to use proceeds to expand and upgrade its existing hospitals while pursuing acquisitions to grow beyond just two facilities. Scaling up seems essential if the company wants to boost revenue and improve profitability.

There's a recent precedent here. Concord Healthcare (2453)—a private hospital operator focused on cancer treatment—went public in Hong Kong last year. But Concord's post-IPO performance hasn't exactly been inspiring. Its shares are down more than 80% from their listing price, which doesn't exactly scream "success story" for the sector.

BenQ BM may be hoping that recent strong investor sentiment around Chinese stocks will carry it across the finish line on its third attempt. But hoping for good market vibes to overcome uninspiring financials is a risky bet. When your revenue is shrinking, your margins are compressing, you're operating at capacity with limited expansion options, and you control less than half a percent of your market, it's hard to craft a compelling growth narrative.

Will the third time be the charm? Maybe. But investors might be forgiven for wondering whether this is persistence or just wishful thinking. The fundamentals tell a challenging story, and no amount of retry attempts can change what's actually happening in the business. BenQ BM faces real structural headwinds in a tough industry, and its latest prospectus doesn't hide that fact.

Back to News

BenQ BM Takes Another Shot at Hong Kong IPO After Two Failed Attempts

MarketDash Editorial Team
19 days ago
Private hospital operator BenQ BM is trying for a third time to list in Hong Kong, but shrinking revenues and declining profits may leave investors wondering if the third time really is the charm.

You know what's worse than failing to launch an IPO once? Trying again with financials that haven't gotten any better. That's the situation facing BenQ BM Holding Cayman Corp., a private hospital operator in China that's taking its third crack at a Hong Kong listing after two previous attempts fizzled out.

The company filed a new prospectus last week, reviving a listing plan that first launched back in April 2024. BenQ BM is majority owned by Qisda (2352.TW), a Taiwan-listed company known globally for its LCD displays and projectors. But if you're thinking this is a story about tech expansion into healthcare with Silicon Valley-style growth numbers, think again.

The Promise and the Problem

On paper, private healthcare in China sounds like a great investment story. The population is aging rapidly, the middle class is expanding, and people increasingly want better service than what they get at overcrowded public hospitals. Who hasn't heard horror stories about the cattle-call experience at massive state-run medical facilities?

But reality is messier than the pitch deck. Private hospitals in China face intense regulatory scrutiny because, well, they're dealing with public health. They compete against government-backed public hospitals that are under pressure to operate more profitably. Hiring qualified doctors is harder when public hospitals can offer better job security and benefits. There's also lingering public skepticism that private operators might put profits ahead of patient care. And let's not forget the basic economics: private hospitals are more expensive to run because they don't get the cost advantages and connections that state-owned peers enjoy.

BenQ BM's financial performance illustrates these challenges vividly. Revenue slipped 1% to 2.7 billion yuan ($380 million) in 2024 from the prior year, and declined by a similar amount year-on-year in the first half of 2025. Worse, profitability is deteriorating steadily. The company's net margin dropped from 6.2% in 2023 to 4.1% in 2024, then fell further to 3.7% in the first half of this year. That's not the trajectory investors typically get excited about.

Maxed Out and Squeezed

A big part of BenQ BM's revenue problem comes down to physical space. The company operates two hospitals: Nanjing BenQ Hospital, a Grade-A Class 3 facility that opened in 2008, and Suzhou BenQ Hospital, a Class 3 general hospital established in 2013. Together they have 1,850 beds as of the end of June, a number that hasn't budged since Nanjing added 150 beds in 2023.

The Nanjing facility is so full that its bed occupancy rate exceeds 100% with temporary beds in use. It's essentially maxed out. Suzhou isn't much better, running at nearly 90% occupancy. When you're already at capacity, there's not much room to grow inpatient revenue, and inpatient services account for just over half of BenQ BM's total revenue.

Then there's the regulatory squeeze. Three years ago, Jiangsu province (where both hospitals are located) introduced a diagnosis-related group (DRG) payment system. Under this scheme, China's public medical insurance reimburses hospitals at standardized rates for inpatient services based on diagnosis categories, rather than actual treatment costs. If those standardized payments don't cover what it actually costs to treat someone, the hospital eats the difference.

Since the DRG system rolled out, average spending per inpatient visit at both BenQ hospitals has declined substantially. Average spending per outpatient visit has also fallen, even as visitor numbers increased, thanks to a government program for centralized drug procurement aimed at lowering drug prices. Add in adjustments to reimbursement rules for certain diagnostic procedures, and you've got a picture of the Chinese government systematically trying to keep healthcare affordable for its national health plan and patients—which is great policy, but not great for hospital margins.

Sure, the centralized drug purchasing program has helped BenQ BM reduce pharmaceutical costs somewhat. But the broader revenue pressure from regulatory changes shows just how much the company's fortunes depend on government policy in this heavily regulated industry.

David Among Many Goliaths

Competition isn't doing BenQ BM any favors either. The company controls a minuscule 0.4% market share among private for-profit hospital operators in China, according to its prospectus. Its Nanjing hospital is the largest in Jiangsu province but still only commands 2% of that provincial market.

Zoom out to include public hospitals, and BenQ's position looks even tinier. Private hospitals collectively generated 944.7 billion yuan in revenue last year—less than a quarter of what government-owned hospitals brought in.

To stay competitive, BenQ BM needs to hire top-tier doctors, which doesn't come cheap. Employee expenses have climbed due to new hires, especially senior professionals like chief doctors. That's putting pressure on gross margin, which slid to 15.9% in the first half of 2025 from 19.3% a year earlier.

The Growth Gambit

If BenQ BM does manage to pull off this IPO, the company plans to use proceeds to expand and upgrade its existing hospitals while pursuing acquisitions to grow beyond just two facilities. Scaling up seems essential if the company wants to boost revenue and improve profitability.

There's a recent precedent here. Concord Healthcare (2453)—a private hospital operator focused on cancer treatment—went public in Hong Kong last year. But Concord's post-IPO performance hasn't exactly been inspiring. Its shares are down more than 80% from their listing price, which doesn't exactly scream "success story" for the sector.

BenQ BM may be hoping that recent strong investor sentiment around Chinese stocks will carry it across the finish line on its third attempt. But hoping for good market vibes to overcome uninspiring financials is a risky bet. When your revenue is shrinking, your margins are compressing, you're operating at capacity with limited expansion options, and you control less than half a percent of your market, it's hard to craft a compelling growth narrative.

Will the third time be the charm? Maybe. But investors might be forgiven for wondering whether this is persistence or just wishful thinking. The fundamentals tell a challenging story, and no amount of retry attempts can change what's actually happening in the business. BenQ BM faces real structural headwinds in a tough industry, and its latest prospectus doesn't hide that fact.